Key result
Albuminuria is linked to ~51% higher non-CV death per SD in CAD patients with CKD.
Why the study?
Does elevated UACR predict cause-specific mortality in CKD patients with suspected or known CAD, depending on the presence of albuminuria?
Cohort (n=1,078)
Does elevated UACR predict cause-specific mortality in CKD patients with suspected or known CAD, depending on the presence of albuminuria?
Answers are grounded in this paper and cite their sources.
In CKD patients with CAD, higher UACR predicts non-cardiovascular mortality only in those with baseline albuminuria, highlighting its role as a marker of systemic vulnerability.
Background The urinary albumin-to-creatinine ratio (UACR) is an important indicator of kidney damage. A meta-analysis indicates that a UACR of 30 mg/g or greater is associated with an increased risk of coronary artery disease (CAD), cardiovascular (CV) mortality, and all-cause mortality in the general population. Recent studies have suggested that all-cause mortality increase with an elevated UACR, even within the normal range of less than 30 mg/g. However, impact of albuminuria (UACR>30mg/g) on the associations of UACR with cause-specific mortality in chronic kidney disease (CKD) patients with suspected or known CAD are unclear. Methods UACR was measured in 1,078 CKD (defined as an estimated glomerular rate [eGFR] of less than 60 mL/min/1.73 m2) patients (432 with and 646 without albuminuria) with suspected or known CAD enrolled in the EXCEED-J study. The outcomes were all-cause death, CV death, non-CV death, cancer death, and non-CV-non-cancer death. Patients were followed up over a 6-year period. Results During the follow-up, 132 (30.6%) and 98 (15.2%) deaths occurred, including 53 (12.3%) and 26 (4.0%) CV deaths, 67 (15.5%) and 56 (8.7%) non-CV deaths, 22 (5.1%) and 25 (3.9%) cancer death, 45 (10.4%) and 30 (4.6%) non-CV-non-cancer death and 12 (2.8%) and 16 (2.5%) undetermined deaths in CKD patients with and without albuminuria, respectively. After adjustment for potential clinical confounders and established CV biomarkers, log-transformed (Ln-) UACR was significantly associated with non-CV death (hazard ratio [HR] for 1-standard-deviation increase, 1.51; 95% confidence interval [CI], 1.14–2.01) and non-CV-non-cancer death (HR, 1.75; 95% CI, 1.23–2.48), but not with all-cause death (HR, 1.17; 95% CI, 0.95–1.45), CV death (HR, 0.96; 95% CI, 0.67–1.36), or cancer death (HR, 1.15; 95% CI, 0.68–1.94) in CKD patients with albuminuria; whereas Ln-UACR was significantly and inversely associated with CV death (HR, 0.74; 95% CI, 0.56–0.99), but not with all-cause death (HR, 0.99; 95% CI, 0.80–1.22), non-CV death (HR, 1.12; 95% CI, 0.81–1.55), cancer death (HR, 1.20; 95% CI, 0.70–2.07) or non-CV-non-cancer death (HR, 1.25; 95% CI, 0.75–2.08) in CKD patients without albuminuria. Conclusions Among CKD patients with suspected or known CAD, an increase in UACR was independently associated with non-CV and non-CV-non-cancer mortality in the presence of albuminuria, but not associated with any outcomes in the absence of albuminuria.
No takes yet. Share an insight, caveat, or question.
Wada et al. (2025) conducted a cohort in Chronic kidney disease with suspected or known coronary artery disease (n=1,078). Albuminuria (UACR > 30 mg/g) vs. No albuminuria was evaluated on Non-CV death (HR 1.51, 95% CI 1.14-2.01). In CKD patients with CAD, albuminuria was associated with higher non-CV death, with a 1-SD increase in Ln-UACR yielding an HR of 1.51 for non-CV death.
Synapse has enriched 10 related papers. Consider them for comparative context: